OncoMatch/Clinical Trials/NCT07209878

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

Is NCT07209878 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies 68Ga-PSMA-11 for prostate cancer (adenocarcinoma).

Phase 2/3RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT07209878Data as of May 2026

Treatment: 68Ga-PSMA-11 — 68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify